CStone Pharmaceuticals
HKEX:2616

Watchlist Manager
CStone Pharmaceuticals Logo
CStone Pharmaceuticals
HKEX:2616
Watchlist
Price: 6.12 HKD 6.43% Market Closed
Market Cap: 9B HKD

Gross Margin
CStone Pharmaceuticals

-12.2%
Current
51%
Average
63.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
-12.2%
=
Gross Profit
-24.7m
/
Revenue
202.5m

Gross Margin Across Competitors

No Stocks Found

CStone Pharmaceuticals
Glance View

Market Cap
8.4B HKD
Industry
Biotechnology

Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 264 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The firm conducts its businesses mainly in domestic market.

CStone Pharmaceuticals Intrinsic Value
HIDDEN
Show
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
-12.2%
=
Gross Profit
-24.7m
/
Revenue
202.5m
What is the Gross Margin of CStone Pharmaceuticals?

Based on CStone Pharmaceuticals's most recent financial statements, the company has Gross Margin of -12.2%.

Back to Top